Enanta Pharmaceuticals Inc key statistics and ratios

In fiscal 2025, Enanta Pharmaceuticals Inc had return on equity of -84.6%, an operating margin of -130.7%, debt equal to 0.0% of equity and a current ratio of 4.21. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Enanta Pharmaceuticals Inc: financial ratios, annual
Fiscal year	2011Sept 2011	2012Sept 2012	2013Sept 2013	2014Sept 2014	2015Sept 2015	2016Sept 2016	2017Sept 2017	2018Sept 2018	2019Sept 2019	2020Sept 2020	2021Sept 2021	2022Sept 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025	LTMJun 2026
Operating margin	60.4%	51.0%	28.2%	39.8%	77.2%	34.9%	23.9%	42.7%	17.9%	−34.0%	−112.9%	−143.7%	−173.2%	−179.9%	−130.7%	−90.0%
Net margin	55.7%	51.3%	30.0%	72.1%	49.1%	24.5%	17.2%	34.8%	22.6%	−29.5%	−81.4%	−141.3%	−169.0%	−171.6%	−125.4%	−96.9%
Free-cash-flow margin	56.3%	53.6%	31.3%	40.1%	46.2%	35.2%	48.8%	12.7%	32.2%	4.6%	−72.9%	−100.9%	−141.7%	−143.0%	−49.2%	−56.6%
Return on equity	—	—	—	26.6%	41.1%	8.6%	6.2%	20.7%	10.8%	−7.9%	−18.5%	−33.8%	−49.7%	−67.2%	−84.6%	−76.3%
Return on assets	—	41.0%	11.4%	25.3%	39.4%	8.2%	5.8%	19.4%	10.3%	−7.4%	−17.1%	−29.9%	−31.9%	−27.7%	−24.9%	−21.9%
Asset turnover	—	0.80	0.38	0.35	0.80	0.33	0.34	0.56	0.45	0.25	0.21	0.21	0.19	0.16	0.20	0.23
Current ratio	—	8.25	23.14	22.75	25.45	29.43	11.33	23.74	17.77	18.08	8.82	10.45	6.73	5.21	4.21	3.76
Debt to equity	—	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	8.0x	—	—	—	—	—	—	—	—	—	—	—	n/m	n/m	n/m	n/m
Effective tax rate	—	0.0%	0.0%	—	37.0%	33.5%	34.3%	22.7%	−1.8%	—	—	—	—	—	—	—
R&D as % of revenue	27.6%	36.2%	52.5%	39.3%	14.4%	45.8%	55.9%	45.9%	69.3%	111.7%	179.4%	190.9%	206.5%	194.4%	163.4%	132.1%
Capital spending as % of revenue	1.1%	0.6%	1.9%	2.2%	1.5%	5.4%	2.4%	1.4%	2.6%	1.2%	0.8%	2.5%	11.4%	26.5%	19.7%	2.5%
Free cash flow ÷ net income	101.1%	104.5%	104.4%	55.6%	94.1%	143.4%	283.2%	36.5%	142.3%	—	—	—	—	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Enanta Pharmaceuticals Inc: financial ratios, quarterly
Quarter	2024 Q4Sept 2024	2025 Q1Dec 2024	2025 Q2Mar 2025	2025 Q3Jun 2025	2025 Q4Sept 2025	2026 Q1Dec 2025	2026 Q2Mar 2026	2026 Q3Jun 2026
Operating margin	−204.4%	−138.8%	−164.3%	−103.2%	−121.6%	−60.5%	−69.1%	−120.0%
Net margin	−197.3%	−131.4%	−151.7%	−99.7%	−123.6%	−64.1%	−76.3%	−135.8%
Free-cash-flow margin	−132.5%	−150.6%	−107.4%	94.7%	−52.5%	−63.6%	−41.8%	−69.5%
Current ratio	5.21	5.47	5.29	5.00	4.21	4.44	3.84	3.76
R&D as % of revenue	210.7%	163.1%	188.0%	148.6%	157.4%	112.1%	113.3%	154.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · June 30, 2026

What it owns · $297m

Short-term assets $204mLonger-term assets $93m

What it owes, and who funded it · $297m

Short-term liabilities $54mLonger-term liabilities $142mShareholders' equity $101m

Short-term assets cover short-term liabilities $204m of assets due within a year against $54m of liabilities due within a year.
Short-term assets cover long-term liabilities $204m short-term assets against $142m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$59m against $13m of interest.

From Enanta Pharmaceuticals Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

17 /100

Weak moat

How hard Enanta Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -19.9% of total assets over 10 years.
Durability 10 / 20

Operating margin has been a median -94.2%; its worst year was -170.7%.
Cash conversion 3 / 20

Free cash flow was positive in 3 of 10 years, at a median -61.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (22 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ABCL vs ENTA CUVL vs ENTA CYTK vs ENTA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Enanta Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Enanta Pharmaceuticals Inc.